Compare Kissei Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 89.25
2
Low Debt Company with Strong Long Term Fundamental Strength
3
Flat results in Jun 25
4
With ROE of 6.96%, it has a very attractive valuation with a 0.96 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 219,911 Million (Small Cap)
14.00
NA
0.00%
-0.29
7.72%
1.04
Revenue and Profits:
Net Sales:
22,191 Million
(Quarterly Results - Jun 2025)
Net Profit:
4,520 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.97%
0%
12.97%
6 Months
1.8%
0%
1.8%
1 Year
22.27%
0%
22.27%
2 Years
44.96%
0%
44.96%
3 Years
84.15%
0%
84.15%
4 Years
93.26%
0%
93.26%
5 Years
96.1%
0%
96.1%
Kissei Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.91%
EBIT Growth (5y)
25.47%
EBIT to Interest (avg)
89.25
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.38
Tax Ratio
23.28%
Dividend Payout Ratio
36.47%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
1.34%
ROE (avg)
5.25%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.96
EV to EBIT
26.65
EV to EBITDA
14.81
EV to Capital Employed
0.95
EV to Sales
1.74
PEG Ratio
0.39
Dividend Yield
0.01%
ROCE (Latest)
3.57%
ROE (Latest)
6.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2013
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
22,191.00
21,164.00
4.85%
Operating Profit (PBDIT) excl Other Income
3,197.00
3,279.00
-2.50%
Interest
6.00
4.00
50.00%
Exceptional Items
116.00
-70.00
265.71%
Consolidate Net Profit
4,520.00
4,105.00
10.11%
Operating Profit Margin (Excl OI)
95.00%
102.00%
-0.70%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 4.85% vs 9.58% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 10.11% vs 23.53% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
88,330.00
75,579.00
16.87%
Operating Profit (PBDIT) excl Other Income
10,570.00
8,271.00
27.80%
Interest
21.00
18.00
16.67%
Exceptional Items
-3,203.00
306.00
-1,146.73%
Consolidate Net Profit
11,975.00
11,289.00
6.08%
Operating Profit Margin (Excl OI)
65.40%
53.10%
1.23%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 16.87% vs 11.98% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 6.08% vs 6.16% in Mar 2024
About Kissei Pharmaceutical Co., Ltd. 
Kissei Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






